Abstract 164P
Background
After curative surgery for stage II colon cancer (CC-II), only patients with high-risk features (pT4 tumor and MSS status) are offered adjuvant chemotherapy (ACT) in the Netherlands. Nevertheless, 15% of CC-II patients develop a recurrence. Post-operative circulating tumor DNA (ctDNA) is a prognostic biomarker that could improve selection of patients that may benefit from ACT. We performed an early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for ACT in CC-II in the Netherlands.
Methods
The validated PATTERN model, which simulates the course of disease from diagnosis till death in CC-II, was supplemented with data on the prognostic value of ctDNA from the Dutch PLCRC-MEDOCC study. Five strategies for selecting patients for ACT were evaluated: current guideline strategy (pT4 and MSS), ctDNA-only strategy, and three combination strategies of ctDNA in addition to pT4 and MSS status. For each strategy, we estimated costs, (quality-adjusted) life-years (QALYs), recurrences and CC deaths. The impact of uncertainty concerning strategy adherence, treatment effect of ACT, costs of ctDNA testing, and test performance on cost-effectiveness was assessed in sensitivity analyses.
Results
Model predictions showed that the ctDNA-only strategy was less effective (more recurrences, less QALYs) and that the combination strategies were more effective (less recurrences, more QALYs) than the current guideline strategy. From the viewpoint of cost-effectiveness, using a willingness-to-pay threshold of €50.000/QALY, the current guideline strategy was most favorable. Sensitivity analyses showed that the combination strategies could be cost-effective if the costs of ctDNA testing are lower than €1500, and/or if ACT is more effective in ctDNA+ than in ctDNA- patients. Improved ctDNA test had limited impact on the cost-effectiveness.
Conclusions
Selecting patients based on ctDNA status in addition to pT4 and MSS status for ACT can improve patient selection in terms of effectiveness, and can also potentially become a cost-effective strategy. However, more research is needed to investigate the prognostic and predictive value of ctDNA to accurately evaluate the (cost)effectiveness.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amsterdam UMC.
Funding
ZonMW.
Disclosure
G.R. Vink: Financial Interests, Institutional, Sponsor/Funding: BMS, Merck, Servier, Personal Genome Diagnostics, Bayer, Sirtex, Pierre Fabre, Lilly, Delfi Diagnostics. V. Velculescu: Financial Interests, Personal and Institutional, Member of Board of Directors, Stockholder and consultant: Personal Genome Diagnostics, Delfi Diagnostics. G. Meijer: Financial Interests, Personal and Institutional, Member of Board of Directors: CRCbioscreen BV; Financial Interests, Institutional, Research Funding: CZ health insurances; Financial Interests, Institutional, Product Samples, provide materials, equipment and/or sample/genomic analyses: Exact Sciences, Sysmex, Sentinel Ch. SpA, Personal Genome Diagnostics, Delfi, Hartwig Medical Foundation; Other, Personal and Institutional, Other, has several patents pending/issued: Other. D. Van Den Broek: Financial Interests, Institutional, Speaker, Consultant, Advisor: Roche diagnostics. M. Koopman: Financial Interests, Institutional, Advisory Board, advisory board and speaker: Pierre Fabre; Financial Interests, Institutional, Advisory Board: MSD, Bayer; Financial Interests, Institutional, Advisory Board, Advisory Board, Speaker: Servier; Financial Interests, Institutional, Invited Speaker: Merck, BMS; Financial Interests, Institutional, Trial Chair: servier; Financial Interests, Institutional, Research Grant: Servier, Roche, Bayer, Bristol Myers Squibb, Merck, Personal Genomics Diagnostics, Sirtex, Pierre Fabre; Financial Interests, Institutional, Funding: Pierre Fabre, Amgen, Nordic Farma, Novartis, Merck, Servier, BMS; Non-Financial Interests, Leadership Role, Vice-Chair of DCCG: Dutch Colorectal Cancer Group; Non-Financial Interests, Advisory Role, Member of KWF scientific board: KWF; Non-Financial Interests, Other, ESMO faculty member for the Gastro-Intestinal Tumours – colorectal cancer: ESMO; Non-Financial Interests, Advisory Role, expert member of committee “regie op registers dure geneesmiddelen” ZINNL: ZiNNL; Non-Financial Interests, Advisory Role, CRC expert on Kanker.nl platform for answering online CRC questions of CRC (non) patients: Patient respresentative organisation (Kanker.nl); Non-Financial Interests, Leadership Role, chair of RWD & DH working group: ESMO; Other, PI of the Dutch Prospective Colorectal Cancer Cohort study: PLCRC project. J.M.L. Roodhart: Financial Interests, Institutional, Sponsor/Funding: Bayer, BMS, Merck Serono, Pierre Fabre, Servier, HUB 4 organoids, Cleara Biotech. R. Fijneman: Financial Interests, Institutional, Sponsor/Funding: Cergentis BV, Personal Genome Diagnostics, Delfi Diagnostics, MERCK BV; Other, Personal and Institutional, Other, has several patents pending: Other. V.P. Retel: Financial Interests, Personal and Institutional, Funding: Intuitive BV. All other authors have declared no conflicts of interest.
Resources from the same session
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01